On 23rd June 2020, the Extraordinary General Meeting of shareholders of Helix Immuno-Oncology S.A. (“Company”) adopted a resolution concerning:
-
An increase in the initial capital of the Company by the amount of 220,000 PLN (two hundred twenty thousand PLN) through emission of 2.200.000 (two million twenty hundred thousand) common registered shares, each with the nominal value of 0.10 PLN (10/100 PLN), marked as series B, while depriving hitherto shareholders of the stock right in whole and the right to change the charter of the Company.
-
Adoption of a consolidated text of the charter of the Company.
As a consequence of adoption of the above-mentioned resolutions by the Extraordinary General Meeting of shareholders of the Company, 2,200,000 (two million twenty hundred thousand) common registered shares, each with the nominal value of 0.10 PLN (10/100 PLN), marked as series B, were acquired by the JR Holding Alternatywna Spółka Inwestycyjna S.A. company with the registered office in Kraków (Poland) through private placing. Series B shares were acquired in return for cash contribution. The issue price of series B shares is 1.35 PLN (one 10/100 PLN) per share, i.e. the total cash contribution of the investor amounted to 2,970,000 PLN (two million nine hundred seventy thousand PLN). The shares acquisition agreement was concluded on 24th June 2020. The shares acquired by the investor constitute 16.64% share in the increased initial capital of the Company and give 2,200,000 (two million two hundred thousand) votes that constitute – upon registration of the increase in the initial capital of the Company by the registry court – 16.64% of the total number of votes.